Li, Jialun, Xu, Zhi, Nishio Ayre, Wayne ![]() ![]() |
![]() |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (603kB) |
Abstract
Periodontitis is a chronic inflammatory disease characterized by gingival inflammation, alveolar bone resorption, and periodontal tissue destruction. Complement activation, particularly through the C3 component, plays a critical role in the inflammatory processes underlying periodontitis. AMY-101, a selective inhibitor of complement C3, has demonstrated significant potential in modulating complement activity and mitigating periodontal inflammation. This study comprehensively evaluates AMY-101’s effects through in vitro, preclinical, and clinical studies. Mechanistic investigations revealed that AMY-101 effectively suppresses pro-inflammatory cytokines and matrix metalloproteinases (MMPs), reducing tissue destruction. Preclinical models confirmed AMY-101’s ability to improve clinical parameters such as probing pocket depth, attachment loss, and bone preservation. Moreover, clinical trials demonstrated AMY-101’s safety and efficacy in reducing gingival inflammation and bleeding without serious adverse events. These findings highlight AMY-101’s therapeutic potential for periodontitis and broader applicability in other complement-driven inflammatory diseases.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Schools > Dentistry |
Funders: | National Natural Science Foundation of China, Innovation and Entrepreneurship Training Program for Chinese Medical University Students |
Date of First Compliant Deposit: | 10 April 2025 |
Date of Acceptance: | 8 April 2025 |
Last Modified: | 16 May 2025 09:47 |
URI: | https://orca.cardiff.ac.uk/id/eprint/177575 |
Actions (repository staff only)
![]() |
Edit Item |